Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.
- Revenue
- +3.07%
- EPS
- −13.5%
- Free cash flow
- +29.8%
- Total debt
- −7.50%
Quarter to September 2026, against a year earlier
Follow ZBH
Alert me
Zimmer Biomet Holdings, Inc. (ZBH) EV/Sales
As of 5 November 2026, Zimmer Biomet Holdings, Inc. (ZBH) trades at a EV/Sales of 3.2×. Over the past ten years it has ranged from 2.7× (May 2026) to 7.3× (April 2021); the current reading is higher than 9% of that period. That is above the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.0× | (14.97%) |
| FY2024 | 3.5× | (14.86%) |
| FY2023 | 4.2× | (9.99%) |
| FY2022 | 4.6× | (3.69%) |
| FY2021 | 4.8× | (24.03%) |
| FY2020 | 6.3× | 33.36% |
| FY2019 | 4.7× | 28.81% |
| FY2018 | 3.7× | (16.27%) |
| FY2017 | 4.4× | 8.81% |
| FY2016 | 4.0× | (16.03%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.8× | 1.01% |
| Jun 2026 | 2.8× | (5.43%) |
| Mar 2026 | 2.9× | (2.32%) |
| Dec 2025 | 3.0× | (8.60%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.6× |
| PHG Koninklijke Philips N.V. compare | 1.7× |
| ZBH Zimmer Biomet Holdings, Inc. | 3.2× |
| PODD Insulet Corporation compare | 3.5× |
| GMED Globus Medical, Inc. compare | 3.5× |
| STE STERIS plc compare | 4.2× |
| DXCM DexCom, Inc. compare | 6.2× |
| PEN Penumbra, Inc. compare | 7.7× |
| GKOS Glaukos Corporation compare | 18.8× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on ZBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement